AAAAAA

   
Results: 1-7 |
Results: 7
Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults
Authors: McMahon, D Lederman, M Haas, DW Haubrich, R Stanford, J Cooney, E Horton, J Kelleher, D Ross, L Cutrell, A Lee, D Spreen, W Mellors, JW
Citation: D. Mcmahon et al., Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults, ANTIVIR TH, 6(2), 2001, pp. 105-114
Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir
Authors: Hetherington, S McGuirk, S Powell, G Cutrell, A Naderer, O Spreen, B Lafon, S Pearce, G Steel, H
Citation: S. Hetherington et al., Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir, CLIN THER, 23(10), 2001, pp. 1603-1614
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults - A randomized equivalence trial
Authors: Staszewski, S Keiser, P Montaner, J Raffi, F Gathe, J Brotas, V Hicks, C Hammer, SM Cooper, D Johnson, M Tortell, S Cutrell, A Thorborn, D Isaacs, R Hetherington, S Steel, H Spreen, W
Citation: S. Staszewski et al., Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults - A randomized equivalence trial, J AM MED A, 285(9), 2001, pp. 1155-1163
A randomized, double-blind study of triple nucleoside therapy of abacavir,lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children
Authors: Saez-Llorens, X Nelson, RP Emmanuel, P Wiznia, A Mitchell, C Church, JA Sleasman, J Van Dyke, R Richardson, CG Cutrell, A Spreen, W Hetherington, S
Citation: X. Saez-llorens et al., A randomized, double-blind study of triple nucleoside therapy of abacavir,lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children, PEDIATRICS, 107(1), 2001, pp. NIL_25-NIL_35
The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial
Authors: Katlama, C Clotet, B Plettenberg, A Jost, J Arasteh, K Bernasconi, E Jeantils, V Cutrell, A Stone, C Ait-Khaled, M Purdon, S
Citation: C. Katlama et al., The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial, AIDS, 14(7), 2000, pp. 781-789
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy
Authors: Miller, V Ait-Khaled, M Stone, C Griffin, P Mesogiti, D Cutrell, A Harrigan, R Staszewski, S Katlama, C Pearce, G Tisdale, M
Citation: V. Miller et al., HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy, AIDS, 14(2), 2000, pp. 163-171
Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase
Authors: Lederman, MM McKinnis, R Kelleher, D Cutrell, A Mellors, J Neisler, M Cooney, E Haas, DW Haubrich, R Stanford, J Horton, J Landay, A Spreen, W
Citation: Mm. Lederman et al., Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase, AIDS, 14(17), 2000, pp. 2635-2642
Risultati: 1-7 |